QuintT, BrunnerPM, SinzC, et al.Dupilumab for the treatment of atopic Dermatitis® in an austrian cohort-real-life data shows rosacea-like folliculitis. J Clin Med, 2020; 9(4):1241. doi:10.3390/jcm9041241
2.
FrancuzikW, AlexiouA, WormM. Safety of dupilumab in patients with atopic Dermatitis®: expert opinion. Expert Opin Drug Saf, 2021; 20(9):997–1004. doi:10.1080/14740338.2021.1939673
3.
van ZuurenEJ, ArentsBWM, van der LindenMMD, et al.Rosacea: new concepts in classification and treatment. Am J Clin Dermatol, 2021; 22(4):457–465. doi:10.1007/s40257-021-00595-7
4.
RussoF, RizzoA, SantiF, et al.A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic Dermatitis®. Int J Dermatol, 2022; 61(6). doi:10.1111/ijd.15871
5.
VerzìAE, BroggiG, MicaliG, et al.Line-field confocal optical coherence tomography of psoriasis, eczema and lichen planus: a case series with histopathological correlation. J Eur Acad Dermatol Venereol, 2022; 36(10):1884–1889. doi:10.1111/jdv.18293
